The pharmaceutical industry is entering a transformative period driven by the global demand for equitable access to life-saving therapies, escalating healthcare expenditure and the increasing prevalence of complex chronic diseases. In this evolving landscape, biosimilars have emerged as a scientifically sophisticated and economically indispensable category of therapeutics. They represent highly similar alternatives to reference biological medicines and carry the potential to redefine global healthcare delivery by enhancing accessibility, reducing treatment costs and fostering sustainable innovation. This review offers an astute and comprehensive analysis of the scientific, economic, regulatory, technological and clinical forces that collectively position biosimilars as the dominant therapeutic class of the upcoming decades. Through an exploration of manufacturing advances, analytical progress, physician acceptance, patient perception and expanding therapeutic domains, the article establishes biosimilars as the future cornerstone of pharmaceutical evolution. It concludes that biosimilars are not an auxiliary development but an inevitable trajectory that will fundamentally recast the structure, economics and therapeutic ethos of the pharmaceutical industry worldwide.
Loading....